Antimicrobial Resistance (AMR) is a serious and increasing threat to global health security and impacts the efficacy of medicines we have come to rely on, made possible by our ability to prevent and treat infections. Vaccination is a complementary tool in the fight against AMR: vaccines reduce the need for and reliance on antibiotics and can also reduce development of further resistance.
However, the topic of vaccination in countries’ AMR National Action Plans (NAPs) has received limited attention. Given that AMR NAPs drive policies to mitigate AMR, there is a clear case for recognizing vaccination as a key pillar for change and outlining well-defined goals for vaccination in NAPs to ensure AMR is approached in a holistic and sustainable manner.
Charles River Associates (CRA) was asked by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) to analyze the landscape around NAPs and the positioning of vaccines as a complementary strategy in the fight against AMR, in terms of recognizing the role of vaccination and committing to corresponding objectives. CRA provides insights on how this support could be strengthened to ensure effective and coordinated action to optimize how vaccination could be used to tackle the growing threat of AMR.
To read more about our findings and the lessons for future AMR policy, please download a copy of our report here.